A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2016
At a glance
- Drugs Erlotinib (Primary) ; Pralatrexate (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.